Yale University CRS

Site Details

LOCATION

135 College Street

Suite 323

New Haven, CT. 06510

1-203-737-4040

Get Directions

SiteType

CRS

CRS Coordinator

Laurie Andrews

laurie.andrews@yale.edu

203-785-3557

CRS Leader

Nikhil Seval, M.D.

nikhil.seval@yale.edu

203-919-7300

Site Trials

HIV comorbidities and complications

Closed to accrual

A5332: REPRIEVE Trial

In this study, people between the ages of 40 and 75 with HIV will be randomized (like flipping a coin) to take the pill pitavastatin OR a placebo (non-active pill) to see if pitavastatin can help prevent heart disease and death in people who are taking HIV medication. You will not know if you are taking pitavastatin or placebo. The REPRIEVE trial will enroll about 7500 people from several countries.

COVID-19 and Mpox

Open and enrolling

A5418: A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Disease

A5418 (STOMP) is a study of tecovirimat (also known as TPOXX) for the treatment of human monkeypox virus (HMPXV) disease.